

# Eleonora AricÃ²

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9445332/publications.pdf>

Version: 2024-02-01

32  
papers

1,060  
citations

471509

17  
h-index

414414

32  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1810  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19. Cytokine and Growth Factor Reviews, 2022, 63, 23-33.	7.2	7
2	Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. Cells, 2021, 10, 845.	4.1	4
3	Chronic Isolation Stress Affects Central Neuroendocrine Signaling Leading to a Metabolically Active Microenvironment in a Mouse Model of Breast Cancer. Frontiers in Behavioral Neuroscience, 2021, 15, 660738.	2.0	11
4	Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 584.	1.6	3
5	Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?. Cytokine and Growth Factor Reviews, 2020, 54, 43-50.	7.2	19
6	In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?. Frontiers in Immunology, 2019, 10, 2303.	4.8	11
7	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN $\gamma$ -Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	7.0	34
8	Dendritic cells modulate c $\alpha$ ckit expression on the edge between activation and death. European Journal of Immunology, 2019, 49, 534-545.	2.9	7
9	Meningeal inflammation changes the balance of TNF signalling in cortical grey matter in multiple sclerosis. Journal of Neuroinflammation, 2019, 16, 259.	7.2	79
10	Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. Cancers, 2019, 11, 1943.	3.7	73
11	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. Cancer Immunology Research, 2018, 6, 658-670.	3.4	34
12	Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells. Journal of Molecular Medicine, 2018, 96, 211-221.	3.9	29
13	Role of interferon regulatory factor 1 in governing T $\alpha$ reg depletion, T $\beta$ h1 polarization, inflammasome activation and antitumor efficacy of cyclophosphamide. International Journal of Cancer, 2018, 142, 976-987.	5.1	32
14	From Traumatic Childhood to Cocaine Abuse: The Critical Function of the Immune System. Biological Psychiatry, 2018, 84, 905-916.	1.3	56
15	Social threat exposure in juvenile mice promotes cocaine $\alpha$ seeking by altering blood clotting and brain vasculature. Addiction Biology, 2017, 22, 911-922.	2.6	13
16	Chemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis. Oncotarget, 2016, 7, 59754-59765.	1.8	4
17	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. Journal of Translational Medicine, 2015, 13, 139.	4.4	36
18	A tumor-promoting mechanism mediated by retrotransposon-encoded reverse transcriptase is active in human transformed cell lines. Oncotarget, 2013, 4, 2271-2287.	1.8	41

#	ARTICLE	IF	CITATIONS
19	Interferon- $\beta$ as Antiviral and Antitumor Vaccine Adjuvants: Mechanisms of Action and Response Signature. <i>Journal of Interferon and Cytokine Research</i> , 2012, 32, 235-247.	1.2	41
20	Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. <i>Cancer Research</i> , 2011, 71, 3528-3539.	0.9	72
21	MHV-68 producing mIFN $\beta$ 1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68. <i>Vaccine</i> , 2011, 29, 3935-3944.	3.8	5
22	Concomitant detection of IFN $\beta$ signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFN $\beta$ -treated subjects at early times after repeated local cytokine treatments. <i>Journal of Translational Medicine</i> , 2011, 9, 67.	4.4	16
23	Activation of TNF receptor 2 in microglia promotes induction of anti-inflammatory pathways. <i>Molecular and Cellular Neurosciences</i> , 2010, 45, 234-244.	2.2	93
24	Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. <i>International Journal of Cancer</i> , 2009, 124, 130-139.	5.1	103
25	Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. <i>BMC Bioinformatics</i> , 2008, 9, S5.	2.6	30
26	Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. <i>Genome Biology</i> , 2007, 8, R8.	9.6	100
27	Microarray Analysis for Monitoring the Response to Interferon. <i>Journal of Immunotherapy</i> , 2005, 28, 619-620.	2.4	2
28	Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. <i>Journal of Translational Medicine</i> , 2005, 3, 24.	4.4	24
29	Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. <i>Journal of Translational Medicine</i> , 2005, 3, 45.	4.4	41
30	Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection. <i>Vaccine</i> , 2004, 22, 1433-1440.	3.8	12
31	Humoral Immune Response and Protection from Viral Infection in Mice Vaccinated with Inactivated MHV-68: Effects of Type I Interferon. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1081-1088.	1.2	12
32	Type I consensus IFN (IFN-con1) Gene Transfer into KSHV/HHV-8-Infected BCBL-1 Cells Causes Inhibition of Viral Lytic Cycle Activation via Induction of Apoptosis and Abrogates Tumorigenicity in SCID Mice. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 1305-1316.	1.2	12